



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY
820 CHANDLER STREET
FORT DETRICK MD 21702-5014

2 February 2021

Advanced Technology International (ATI)
ATTN: (b) (6), Contracts Manager
315 Sigma Drive
Summerville, SC 29486

Dear (b) (6):

SUBJECT: Revised Project Approval Letter (PAL) for 20-12-COVID19-Diagnostics-001 for “Modified PPD Test for Detection and Scalable Monitoring of the Covid-19 Antibody and Beyond” to Diomics Corporation, PAL Version 2

REF: Request for Project Approval from ATI dated 18 August 2020 for 20-12-COVID19-Diagnostics-001 under OTA W81XWH-15-9-0001

EGS#: MT20012.001

The purpose of this revised PAL is to:

- Reflect a 4-month extension at no additional cost to the Government and incorporate a revised SOW and MPS as an enclosure.

In support of the U.S. Army Medical Research and Development Command (USAMRDC), ATI, on behalf of the Medical Technology Enterprise Consortium (MTEC) issued Request for Project Proposal (RPP) number MTEC-20-12-COVID19-Diagnostics on 1 May 2020. Both current and prospective members of the MTEC submitted Enhanced White Papers in response to this RPP, in accordance with the terms of the RPP. (b) (4)

Subsequently, the Government evaluated those Enhanced White Papers that passed the Government’s initial screening process in accordance with the stated evaluation criteria. (b) (4)

Based upon the evaluation of Diomics Corporation’s proposal (20-12-COVID19-Diagnostics-001) entitled, “Modified PPD Test for Detection and Scalable Monitoring of the Covid-19 Antibody and Beyond,” and ATI’s request for PAL (which includes the Statement of Work (SOW), inclusive of an acceptable milestone schedule), the Government issued an initial Project Approval Letter (PAL), dated 27 August 2020, which authorized ATI to issue a Research Project Award (RPA) to Diomics Corporation for the subject initiative. As stated in the aforementioned PAL, a separate Other Transaction Agreement (OTA) Task Order modification, W81XWH-20-9-0015-P00001 was issued which fully funded Diomics Corporation’s awarded costs.

The Sponsor Office Technical Representative (SOTR) for this RPA is (b) (6)

SUBJECT: Revised PAL for 20-12-COVID19-Diagnostics-001 for “Modified PPD Test for Detection and Scalable Monitoring of the Covid-19 Antibody and Beyond” to Diomics Corporation, PAL Version 2

The period of performance (POP) of the Research Project Award has been extended from 8 months to approximately 12 months as a result of this Revised PAL for a new end date of 9 June 2021. Note, however, that the POP within the OTA Task Order, W81XWH-20-9-0015, includes additional time to account for the final negotiations between ATI and all performers included under the “Wearable Diagnostic for Detection of COVID-19 Infection” Task Order. This additional time is intended to align the end dates for the Task Order and RPAs.

Special Considerations

- a. The Government has not identified any national security restrictions that apply to this RPA.
- b. The following special research considerations are applicable to this award: use of human subjects and animal subjects. Approval from the MRDC Human Research Protections Office (HRPO) must be obtained prior to commencement of the tasks involving human subjects. Additionally, approval from the MRDC Animal Care and Use Review Office (ACURO) must be obtained prior to commencement of the tasks involving animal subjects.

Data Rights

As stated in Diomics Corporation’s proposal entitled, “Modified PPD Test for Detection and Scalable Monitoring of the Covid-19 Antibody and Beyond,” all under this prototype project will be delivered to the Government with unlimited data rights.

Pre-Award Cost Authorization

The Agreements Officer has authorized pre-award costs for the RPA to Diomics Corporation. As the Pre-Award Cost Authorization (PACA) letter was fully executed between ATI and Diomics Corporation on 13 July 2020, the Government agrees to pay allowable costs accrued in the performance of this RPA starting on this date (13 July 2020) through the end of the period of performance in an amount not to exceed \$190,000.00. Additionally, the Agreements Officer authorized the allowance of costs incurred by Diomics Corporation as Cost Share (Anticipated Non-Federal Contribution) starting on this date (13 July 2020).

The total authorized value has been determined fair and reasonable and this proposal has been selected in accordance with the RPP evaluation criteria. The Agreements Officer documented the appropriate use of Section 815 prototype OTA authority at the time of award. The total approved cost to the Government for this effort is Not-to-Exceed (NTE) **\$2,113,146.00** (note that the “Total Program Cost” value listed in the table below of (b) (4) is inclusive of the Anticipated Non-Federal Contribution).

SUBJECT: Revised PAL for 20-12-COVID19-Diagnostics-001 for “Modified PPD Test for Detection and Scalable Monitoring of the Covid-19 Antibody and Beyond” to Diomics Corporation, PAL Version 2

At no time shall the Government’s obligation exceed the funding provided for this RPA.

Government Project Funding	ATI Fixed Fee (Gov’t Funding)	Total Cost to the Government	Anticipated Non-Federal Contribution	Total Program Cost
\$2,113,146.00	\$0.00	\$2,113,146.00	(b) (4)	(b) (4)

Sincerely,

BEST.AMANDA.LEE.1369630896
LEE.1369630896

Digitally signed by
BEST.AMANDA.LEE.1369630896
Date: 2021.02.08 09:10:28
-05'00'

Amanda L. Best
Agreements Officer

CONCURRENCE,

ATI Authorized Representative

Enclosed:
Revised Statement of Work with Milestones, dated January 2021